newsfilter
← Latest News
Business Wire·

Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date

  • The FDA notified Savara Inc. that it will not meet the PDUFA target action date of November 22, 2026 for the molgramostim inhalation solution Biologics License Application.
  • The review of the BLA for treating autoimmune PAP remains ongoing with no revised action date provided by the agency.
  • Molgramostim is an investigational recombinant human GM-CSF delivered via an investigational eFlow Nebulizer System to treat surfactant accumulation in the alveoli caused by autoantibodies.
  • Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases with management experienced in advancing product candidates to approval.
  • The press release includes forward-looking statements regarding FDA review timing, accompanied by a caution regarding risks and uncertainties that could cause actual results to differ from expectations.
Keywords
Biotechnology,Clinical Trials,FDA,Health,Pharmaceutical